Reference : Risk adaptive treatment in Hodgkin's lympoma: reduction of radiation dose and irradiated...

	Document type :	Scientific journals : Article
	Discipline(s) :	Human health sciences : Hematology Human health sciences : Oncology
	To cite this reference:	http://hdl.handle.net/2268/18833

Title :	Risk adaptive treatment in Hodgkin's lympoma: reduction of radiation dose and irradiated volume
Language :	English
Author, co-author :	Coucke, Philippe [Centre Hospitalier Universitaire de Liège - CHU > > Radiothérapie >]
	Barthelemy, Nicole [Centre Hospitalier Universitaire de Liège - CHU > > Radiothérapie >]
	Hustinx, Roland [Centre Hospitalier Universitaire de Liège - CHU > > Médecine nucléaire >]
	Fillet, Georges [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >]
Publication date :	2008
Journal title :	Belgian Journal of Medical Oncology [=BJMO]
Volume :	2
Issue/season :	2
Pages :	85-97
Audience :	National
ISSN :	1784-7141
Keywords :	[en] Hodgkin’s lymphoma ; late effects ; radiotherapy
	[fr] dose ; volume
Abstract :	[en] Treatment–related late complications on nontarget normal tissues and appearance of secondary malignancies are well known side-effects induced by effective treatment regimens currently used in the curative approach of early and advanced Hodgkin’s lymphoma. Radiotherapy (RT) and chemotherapy (CT) can lead to these late complications. Efforts have been conducted to reduce the morbidity and mortality related to these treatments. In particular there has been a progressive shift from radiotherapy used as sole modality to chemotherapy as first line followed by consolidation radiotherapy. As the side-effects of radiotherapy are linked to dose, volume and interaction with chemotherapy, trials have been launched to assess the impact of modifying the characteristics of the radiation treatment. For early-stage Hodgkin’s lymphoma radiotherapy cannot be avoided but dose and volume can be reduced. In advanced Hodgkin’s lymphoma omitting radiotherapy seems reasonable only in case of complete response (CR). The clinical trials allowing such a paradigm shift are highlighted in this review.
Target :	Researchers ; Professionals
Permalink :	http://hdl.handle.net/2268/18833

	File(s) associated to this reference
	Fulltext file(s): File Commentary Version Size Access Open access BJMO%232_08_Coucke[1].pdf No commentary Author postprint 185.14 kB View/Open

All documents in ORBi are protected by a user license.

 

© ULg Library Network |  Feedback |  ORBi legal notices

Dspace v1.5